582 related articles for article (PubMed ID: 30482226)
1. Increasing intratumor C/EBP-β LIP and nitric oxide levels overcome resistance to doxorubicin in triple negative breast cancer.
Salaroglio IC; Gazzano E; Abdullrahman A; Mungo E; Castella B; Abd-Elrahman GEFA; Massaia M; Donadelli M; Rubinstein M; Riganti C; Kopecka J
J Exp Clin Cancer Res; 2018 Nov; 37(1):286. PubMed ID: 30482226
[TBL] [Abstract][Full Text] [Related]
2. Loss of C/EBP-β LIP drives cisplatin resistance in malignant pleural mesothelioma.
Kopecka J; Salaroglio IC; Righi L; Libener R; Orecchia S; Grosso F; Milosevic V; Ananthanarayanan P; Ricci L; Capelletto E; Pradotto M; Napoli F; Di Maio M; Novello S; Rubinstein M; Scagliotti GV; Riganti C
Lung Cancer; 2018 Jun; 120():34-45. PubMed ID: 29748013
[TBL] [Abstract][Full Text] [Related]
3. The role of C/EBP-β LIP in multidrug resistance.
Riganti C; Kopecka J; Panada E; Barak S; Rubinstein M
J Natl Cancer Inst; 2015 Mar; 107(5):. PubMed ID: 25766403
[TBL] [Abstract][Full Text] [Related]
4. Endoplasmic reticulum-targeting doxorubicin: a new tool effective against doxorubicin-resistant osteosarcoma.
Buondonno I; Gazzano E; Tavanti E; Chegaev K; Kopecka J; Fanelli M; Rolando B; Fruttero R; Gasco A; Hattinger C; Serra M; Riganti C
Cell Mol Life Sci; 2019 Feb; 76(3):609-625. PubMed ID: 30430199
[TBL] [Abstract][Full Text] [Related]
5. Glabratephrin reverses doxorubicin resistance in triple negative breast cancer by inhibiting P-glycoprotein.
Abd-Ellatef GEF; Gazzano E; El-Desoky AH; Hamed AR; Kopecka J; Belisario DC; Costamagna C; S Marie MA; Fahmy SR; Abdel-Hamid AZ; Riganti C
Pharmacol Res; 2022 Jan; 175():105975. PubMed ID: 34785319
[TBL] [Abstract][Full Text] [Related]
6. A marine-derived small molecule induces immunogenic cell death against triple-negative breast cancer through ER stress-CHOP pathway.
Wen H; Zhong Y; Yin Y; Qin K; Yang L; Li D; Yu W; Yang C; Deng Z; Hong K
Int J Biol Sci; 2022; 18(7):2898-2913. PubMed ID: 35541893
[TBL] [Abstract][Full Text] [Related]
7. Folate-targeted liposomal nitrooxy-doxorubicin: An effective tool against P-glycoprotein-positive and folate receptor-positive tumors.
Gazzano E; Rolando B; Chegaev K; Salaroglio IC; Kopecka J; Pedrini I; Saponara S; Sorge M; Buondonno I; Stella B; Marengo A; Valoti M; Brancaccio M; Fruttero R; Gasco A; Arpicco S; Riganti C
J Control Release; 2018 Jan; 270():37-52. PubMed ID: 29191785
[TBL] [Abstract][Full Text] [Related]
8. C/EBP-beta regulates endoplasmic reticulum stress-triggered cell death in mouse and human models.
Meir O; Dvash E; Werman A; Rubinstein M
PLoS One; 2010 Mar; 5(3):e9516. PubMed ID: 20209087
[TBL] [Abstract][Full Text] [Related]
9. Dual-target MDM2/MDMX inhibitor increases the sensitization of doxorubicin and inhibits migration and invasion abilities of triple-negative breast cancer cells through activation of TAB1/TAK1/p38 MAPK pathway.
Fan Y; Li M; Ma K; Hu Y; Jing J; Shi Y; Li E; Dong D
Cancer Biol Ther; 2019; 20(5):617-632. PubMed ID: 30462562
[TBL] [Abstract][Full Text] [Related]
10. Peptide mediated active targeting and intelligent particle size reduction-mediated enhanced penetrating of fabricated nanoparticles for triple-negative breast cancer treatment.
Hu G; Chun X; Wang Y; He Q; Gao H
Oncotarget; 2015 Dec; 6(38):41258-74. PubMed ID: 26517810
[TBL] [Abstract][Full Text] [Related]
11. Preclinical Evaluation of Fatty Acid Synthase and EGFR Inhibition in Triple-Negative Breast Cancer.
Giró-Perafita A; Palomeras S; Lum DH; Blancafort A; Viñas G; Oliveras G; Pérez-Bueno F; Sarrats A; Welm AL; Puig T
Clin Cancer Res; 2016 Sep; 22(18):4687-97. PubMed ID: 27106068
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of iNOS as a novel effective targeted therapy against triple-negative breast cancer.
Granados-Principal S; Liu Y; Guevara ML; Blanco E; Choi DS; Qian W; Patel T; Rodriguez AA; Cusimano J; Weiss HL; Zhao H; Landis MD; Dave B; Gross SS; Chang JC
Breast Cancer Res; 2015 Feb; 17(1):25. PubMed ID: 25849745
[TBL] [Abstract][Full Text] [Related]
13. Etoposide and doxorubicin enhance the sensitivity of triple negative breast cancers through modulation of TRAIL-DR5 axis.
Das S; Tripathi N; Siddharth S; Nayak A; Nayak D; Sethy C; Bharatam PV; Kundu CN
Apoptosis; 2017 Oct; 22(10):1205-1224. PubMed ID: 28702823
[TBL] [Abstract][Full Text] [Related]
14. Cross-talk between endoplasmic reticulum (ER) stress and the MEK/ERK pathway potentiates apoptosis in human triple negative breast carcinoma cells: role of a dihydropyrimidone, nifetepimine.
Ghosh S; Adhikary A; Chakraborty S; Bhattacharjee P; Mazumder M; Putatunda S; Gorain M; Chakraborty A; Kundu GC; Das T; Sen PC
J Biol Chem; 2015 Feb; 290(7):3936-49. PubMed ID: 25527500
[TBL] [Abstract][Full Text] [Related]
15. Synergistic Effect of SH003 and Doxorubicin in Triple-negative Breast Cancer.
Woo SM; Kim AJ; Choi YK; Shin YC; Cho SG; Ko SG
Phytother Res; 2016 Nov; 30(11):1817-1823. PubMed ID: 27476488
[TBL] [Abstract][Full Text] [Related]
16. Molecular symbiosis of CHOP and C/EBP beta isoform LIP contributes to endoplasmic reticulum stress-induced apoptosis.
Chiribau CB; Gaccioli F; Huang CC; Yuan CL; Hatzoglou M
Mol Cell Biol; 2010 Jul; 30(14):3722-31. PubMed ID: 20479126
[TBL] [Abstract][Full Text] [Related]
17. MiR-770 suppresses the chemo-resistance and metastasis of triple negative breast cancer via direct targeting of STMN1.
Li Y; Liang Y; Sang Y; Song X; Zhang H; Liu Y; Jiang L; Yang Q
Cell Death Dis; 2018 Jan; 9(1):14. PubMed ID: 29323124
[TBL] [Abstract][Full Text] [Related]
18. CCAAT enhancer binding protein delta activates vesicle associated membrane protein 3 transcription to enhance chemoresistance and extracellular PD-L1 expression in triple-negative breast cancer.
Zhao Y; Yu Y; Li X; Guo A
J Exp Clin Cancer Res; 2024 Apr; 43(1):115. PubMed ID: 38627816
[TBL] [Abstract][Full Text] [Related]
19. P-Glycoprotein Inhibition Sensitizes Human Breast Cancer Cells to Proteasome Inhibitors.
Deshmukh RR; Kim S; Elghoul Y; Dou QP
J Cell Biochem; 2017 May; 118(5):1239-1248. PubMed ID: 27813130
[TBL] [Abstract][Full Text] [Related]
20. Pre-activated human mesenchymal stromal cells in combination with doxorubicin synergistically enhance tumor-suppressive activity in mice.
Yoon N; Park MS; Peltier GC; Lee RH
Cytotherapy; 2015 Oct; 17(10):1332-41. PubMed ID: 26227206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]